1 Thijs RD, Surges R, O'Brien TJ, et al. Epilepsy in adults[J]. Lancet, 2019, 393(10172): 689-701. PMID: 30686584. DOI: 10.1016/S0140-6736(18)32596-0.
2 ?ukawski K, Czuczwar SJ. Understanding mechanisms of drug resistance in epilepsy and strategies for overcoming it[J]. Expert Opin Drug Metab Toxicol, 2021, 17(9): 1075-1090. PMID: 34310255. DOI: 10.1080/17425255.2021.1959912.
3 Chen Y, Yang K, Maru?ic A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement[J]. Ann Intern Med, 2017, 166(2): 128-132. PMID: 27893062. DOI: 10.7326/M16-1565.
4 EEBM. OCEBM levels of evidence[EB/OL]. [2023-07-25]. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence.
5 Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care[J]. CMAJ, 2010, 182(18): E839-E842. PMID: 20603348. PMCID: PMC3001530. DOI: 10.1503/cmaj.090449.
6 WHO. WHO handbook for guideline development, 2nd Edition[EB/OL]. (2014-12-18)[2022-03-22]. https://www.who.int/publications-detail-redirect/9789241548960.
7 Haut SR, Katz M, Masur J, et al. Seizures in the elderly: impact on mental status, mood, and sleep[J]. Epilepsy Behav, 2009, 14(3): 540-544. PMID: 19189862. PMCID: PMC2695969. DOI: 10.1016/j.yebeh.2009.01.005.
8 Ho PH, Leung WCY, Leung IYH, et al. Factors associated with depression in people with epilepsy: a retrospective case-control analysis[J]. Hong Kong Med J, 2020, 26(4): 311-317. PMID: 32611830. DOI: 10.12809/hkmj198310.
9 Tegegne MT, Mossie TB, Awoke AA, et al. Depression and anxiety disorder among epileptic people at Amanuel Specialized Mental Hospital, Addis Ababa, Ethiopia[J]. BMC Psychiatry, 2015, 15: 210. PMID: 26328614. PMCID: PMC4556015. DOI: 10.1186/s12888-015-0589-4.
10 Hendriks MP, Aldenkamp AP, Alpherts WC, et al. Relationships between epilepsy-related factors and memory impairment[J]. Acta Neurol Scand, 2004, 110(5): 291-300. PMID: 15476457. DOI: 10.1111/j.1600-0404.2004.00319.x.
11 Majkowski J, Neto W, Wapenaar R, et al. Time course of adverse events in patients with localization-related epilepsy receiving topiramate added to carbamazepine[J]. Epilepsia, 2005, 46(5): 648-653. PMID: 15857429. DOI: 10.1111/j.1528-1167.2005.35904.x.
12 Bresnahan R, Hounsome J, Jette N, et al. Topiramate add-on therapy for drug-resistant focal epilepsy[J]. Cochrane Database Syst Rev, 2019, 10(10): CD001417. PMID: 31642054. PMCID: PMC6806021. DOI: 10.1002/14651858.CD001417.pub4.
13 O'Connor J, Levy P, Wilson SS. Levetiracetam is as effective as phenytoin for status epilepticus with less adverse events in the ED[J]. Crit Care Med, 2015, 43(12): 6. DOI: 10.1097/01.ccm.0000473848.40708.ea.
14 Delanty N, Jones J, Tonner F. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study[J]. Epilepsia, 2012, 53(1): 111-119. PMID: 22050371. DOI: 10.1111/j.1528-1167.2011.03300.x.
15 Sankar R, Ramsay E, McKay A, et al. A multicenter, outpatient, open-label study to evaluate the dosing, effectiveness, and safety of topiramate as monotherapy in the treatment of epilepsy in clinical practice[J]. Epilepsy Behav, 2009, 15(4): 506-512. PMID: 19643672. DOI: 10.1016/j.yebeh.2009.06.021.
16 Mohan P, Gupta P, Tripathi M, et al. Adverse effect profile of anti epileptic drugs in persons with epilepsy in India: a cross sectional study[J]. Clin Ther, 2015, 37(8): e135-e136. DOI: 10.1016/j.clinthera.2015.05.387.
17 Steinhoff BJ, Klein P, Klitgaard H, et al. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review[J]. Epilepsy Behav, 2021, 118: 107939. PMID: 33839453. DOI: 10.1016/j.yebeh.2021.107939.
18 Harbord MG. Significant anticonvulsant side-effects in children and adolescents[J]. J Clin Neurosci, 2000, 7(3): 213-216. PMID: 10833618. DOI: 10.1054/jocn.1999.0190.
19 Bj?rk MH, Veiby G, Reiter S, et al. Pregnant women with epilepsy: is the risk of peripartum psychiatric symptoms increased?—a prospective, population based cohort study[J]. J Neurol Sci, 2013, 333(S1): E46. DOI: 10.1016/j.jns.2013.07.165.
20 Guilfoyle SM, Wagner JL, Smith G, et al. Early screening and identification of psychological comorbidities in pediatric epilepsy is necessary[J]. Epilepsy Behav, 2012, 25(4): 495-500. PMID: 23153713. DOI: 10.1016/j.yebeh.2012.09.041.
21 Jovic N, Belacevic M. Levetiracetam-induced psychiatric adverse events in children with epilepsy[J]. Eur Neuropsychopharmacol, 2013, 23(Suppl 2): S601. DOI: 10.1016/S0924-977X(13)70956-8.
22 Mula M, Trimble MR, Lhatoo SD, et al. Topiramate and psychiatric adverse events in patients with epilepsy[J]. Epilepsia, 2003, 44(5): 659-663. PMID: 12752464. DOI: 10.1046/j.1528-1157.2003.05402.x.
23 Lattanzi S, Cagnetti C, Foschi N, et al. Adjunctive perampanel in older patients with epilepsy: a multicenter study of clinical practice[J]. Drugs Aging, 2021, 38(7): 603-610. PMID: 34075567. PMCID: PMC8266697. DOI: 10.1007/s40266-021-00865-3.
24 Kanner AM, Wuu J, Faught E, et al. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events[J]. Epilepsy Behav, 2003, 4(5): 548-552. PMID: 14527497. DOI: 10.1016/j.yebeh.2003.07.007.
25 Juhl S, Rubboli G. Add-on perampanel and aggressive behaviour in severe drug-resistant focal epilepsies[J]. Funct Neurol, 2017, 32(4): 215-220. PMID: 29336297. PMCID: PMC5762107.
26 Fain R, Chung S, Yang H, et al. Aggression adverse events with concomitant levetiracetam use in perampanel phase III partial-onset seizure clinical studies[J]. Epilepsy Curr, 2015, 15: 321-322. DOI: 10.1002/central/CN-01081287.
27 Cardenas JF, Rho JM, Ng YT. Reversible lamotrigine-induced neurobehavioral disturbances in children with epilepsy[J]. J Child Neurol, 2010, 25(2): 182-187. PMID: 19494356. DOI: 10.1177/0883073809336874.
28 Zaccara G, Giovannelli F, Maratea D, et al. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine[J]. Seizure, 2013, 22(7): 528-536. PMID: 23623245. DOI: 10.1016/j.seizure.2013.03.016.
29 Wen X, Meador KJ, Loring DW, et al. Is antiepileptic drug use related to depression and suicidal ideation among patients with epilepsy?[J]. Epilepsy Behav, 2010, 19(3): 494-500. PMID: 20880757. DOI: 10.1016/j.yebeh.2010.08.030.
30 Betts T, Goodwin G, Withers RM, et al. Human safety of lamotrigine[J]. Epilepsia, 1991, 32 (Suppl 2): S17-S21. PMID: 1837776. DOI: 10.1111/j.1528-1157.1991.tb05881.x.
31 Namazi S, Borhani-Haghighi A, Karimzadeh I. Adverse reactions to antiepileptic drugs in epileptic outpatients: a cross-sectional study in Iran[J]. Clin Neuropharmacol, 2011, 34(2): 79-83. PMID: 21412202. DOI: 10.1097/WNF.0b013e318210ece0.
32 R?sche J, Kundt G, Weber R, et al. The impact of antiepileptic polytherapy on mood and cognitive function[J]. Acta Neurol Belg, 2011, 111(1): 29-32. PMID: 21510230.
33 Lee JJ, Song HS, Hwang YH, et al. Psychiatric symptoms and quality of life in patients with drug-refractory epilepsy receiving adjunctive levetiracetam therapy[J]. J Clin Neurol, 2011, 7(3): 128-136. PMID: 22087206. PMCID: PMC3212598. DOI: 10.3988/jcn.2011.7.3.128.
34 Rathore JS, Tesar GE, Obuchowski N, et al. Correlations of PHQ-9 with NDDI-E in epilepsy patients: a pilot study[J]. Epilepsy Curr, 2013, 13: 258. DOI: 10.5698/1535-7511-13.s1.
35 Joshi R, Tripathi M, Gupta P, et al. Depression in patients receiving pharmacotherapy for epilepsy: an audit in a tertiary care centre[J]. Pharmacol Rep, 2019, 71(5): 848-854. PMID: 31398575. DOI: 10.1016/j.pharep.2019.04.021.
36 张静, 魏红艳, 左艳芳, 等. 抗癫痫药和脑电图放电指数对癫痫患儿认知功能的影响[J]. 临床和实验医学杂志, 2019, 18(15): 1625-1628. DOI: 10.3969/j.issn.1671-4695.2019.15.017.
37 Yang L, Dong XZ, Cui XH, et al. Comparison of the efficacy and safety of levetiracetam and phenytoin in the treatment of established status epilepticus: a systematic review and meta-analysis[J]. J Clin Neurosci, 2021, 89: 422-429. PMID: 34053822. DOI: 10.1016/j.jocn.2021.05.004.
38 Yang C, Peng Y, Zhang L, et al. Safety and tolerability of lacosamide in patients with epilepsy: a systematic review and meta-analysis[J]. Front Pharmacol, 2021, 12: 694381. PMID: 34616294. PMCID: PMC8488108. DOI: 10.3389/fphar.2021.694381.
39 Steinhoff BJ, Eckhardt K, Doty P, et al. A long-term noninterventional safety study of adjunctive lacosamide therapy in patients with epilepsy and uncontrolled partial-onset seizures[J]. Epilepsy Behav, 2016, 58: 35-43. PMID: 27054272. DOI: 10.1016/j.yebeh.2016.02.041.
40 Davidson KE, Newell J, Alsherbini K, et al. Safety and efficiency of intravenous push lacosamide administration[J]. Neurocrit Care, 2018, 29(3): 491-495. PMID: 29949010. DOI: 10.1007/s12028-018-0560-6.
41 Cook R, Whiteside C, Alsherbini K, et al. Adverse events relating to the use of midazolam infusions for refractory status epilepticus[J]. Crit Care Med, 2019, 47(1): 344. DOI: 10.1097/01.ccm.0000551479.49808.1a.
42 Brandt C, Klein P, Badalamenti V, et al. Safety and tolerability of adjunctive brivaracetam in epilepsy: in-depth pooled analysis[J]. Epilepsy Behav, 2020, 103(Pt A): 106864. PMID: 31937513. DOI: 10.1016/j.yebeh.2019.106864.
43 Kim HK, Hwang IG, Koh IS, et al. Incidence and risk factors of hypotension after intravenous fosphenytoin administration[J]. J Clin Pharm Ther, 2017, 42(5): 561-566. PMID: 28439951. DOI: 10.1111/jcpt.12537.
44 Torian S, Jones GM. 910: high-dose intravenous push lacosamide: safety and efficiency in administration[J]. Crit Care Med, 2022, 50(1): 452. DOI: 10.1097/01.ccm.0000809964.67465.f7.
45 Arnold S, Laloyaux C, Schulz AL, et al. Long-term safety and efficacy of brivaracetam in adults with focal seizures: results from an open-label, multinational, follow-up trial[J]. Epilepsy Res, 2020, 166: 106404. PMID: 32731118. DOI: 10.1016/j.eplepsyres.2020.106404.
46 Guldiken B, Rémi J, Noachtar S. Cardiovascular adverse effects of phenytoin[J]. J Neurol, 2016, 263(5): 861-870. PMID: 26645393. DOI: 10.1007/s00415-015-7967-1.
47 O'Brien J, Klaus S, Jain D, et al. Telemetry monitoring in an epilepsy monitoring unit reveals new arrhythmias in patients on antiepileptic drugs with confirmed arrhythmic side effects[J]. Europace, 2018, 20: i17. DOI: 10.1093/europace/euy015.040.
48 Lee-Lane E, Torabi F, Lacey A, et al. Epilepsy, antiepileptic drugs, and the risk of major cardiovascular events[J]. Epilepsia, 2021, 62(7): 1604-1616. PMID: 34046890. DOI: 10.1111/epi.16930.
49 Weeke LC, Schalkwijk S, Toet MC, et al. Lidocaine-associated cardiac events in newborns with seizures: incidence, symptoms and contributing factors[J]. Neonatology, 2015, 108(2): 130-136. PMID: 26111505. DOI: 10.1159/000430767.
50 Yi?in AK, Alay MT, Seven M. Fetal outcomes of anti-epileptic drug use in pregnancy: teratologic approach[J]. Turk J Neurol, 2021, 27: 27-33. DOI: 10.4274/tnd.2020.42402.
51 Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child[J]. Cochrane Database Syst Rev, 2016, 11(11): CD010224. PMID: 27819746. PMCID: PMC6465055. DOI: 10.1002/14651858.CD010224.pub2.
52 Veroniki AA, Cogo E, Rios P, et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes[J]. BMC Med, 2017, 15(1): 95. PMID: 28472982. PMCID: PMC5418725. DOI: 10.1186/s12916-017-0845-1.
53 Wide K, Winbladh B, Tomson T, et al. Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study[J]. Dev Med Child Neurol, 2000, 42(2): 87-92. PMID: 10698324. DOI: 10.1017/s0012162200000177.
54 Margulis AV, Mitchell AA, Gilboa SM, et al. Use of topiramate in pregnancy and risk of oral clefts[J]. Am J Obstet Gynecol, 2012, 207(5): 405.e1-405.e7. PMID: 22917484. PMCID: PMC3484193. DOI: 10.1016/j.ajog.2012.07.008.
55 Almgren M, K?llén B, Lavebratt C. Population-based study of antiepileptic drug exposure in utero: influence on head circumference in newborns[J]. Seizure, 2009, 18(10): 672-675. PMID: 19828334. DOI: 10.1016/j.seizure.2009.09.002.
56 Jentink J, Dolk H, Loane MA, et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study[J]. BMJ, 2010, 341: c6581. PMID: 21127116. PMCID: PMC2996546. DOI: 10.1136/bmj.c6581.
57 Farmen AH, Grundt J, Tomson T, et al. Intrauterine growth retardation in foetuses of women with epilepsy[J]. Seizure, 2015, 28: 76-80. PMID: 25797889. DOI: 10.1016/j.seizure.2015.02.026.
58 Veiby G, Daltveit AK, Engelsen BA, et al. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy[J]. J Neurol, 2014, 261(3): 579-588. PMID: 24449062. DOI: 10.1007/s00415-013-7239-x.
59 Vajda FJ, O'Brien TJ, Hitchcock A, et al. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months[J]. J Clin Neurosci, 2003, 10(5): 543-549. PMID: 12948456. DOI: 10.1016/s0967-5868(03)00158-9.
60 Wen X, Hartzema A, Delaney JA, et al. Combining adverse pregnancy and perinatal outcomes for women exposed to antiepileptic drugs during pregnancy, using a latent trait model[J]. BMC Pregnancy Childbirth, 2017, 17(1): 10. PMID: 28061833. PMCID: PMC5219655. DOI: 10.1186/s12884-016-1190-7.
61 Artama M, Gissler M, Malm H, et al. Effects of maternal epilepsy and antiepileptic drug use during pregnancy on perinatal health in offspring: nationwide, retrospective cohort study in Finland[J]. Drug Saf, 2013, 36(5): 359-369. PMID: 23615755. DOI: 10.1007/s40264-013-0052-8.
62 Titze K, Koch S, Helge H, et al. Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development[J]. Dev Med Child Neurol, 2008, 50(2): 117-122. PMID: 18177411. DOI: 10.1111/j.1469-8749.2007.02020.x.
63 Tomson T, Battino D, Bonizzoni E, et al. Declining malformation rates with changed antiepileptic drug prescribing: an observational study[J]. Neurology, 2019, 93(9): e831-e840. PMID: 31391249. DOI: 10.1212/WNL.0000000000008001.
64 Vajda FJ, O'Brien TJ, Lander CM, et al. Teratogenesis in repeated pregnancies in antiepileptic drug-treated women[J]. Epilepsia, 2013, 54(1): 181-186. PMID: 22882134. DOI: 10.1111/j.1528-1167.2012.03625.x.
65 Viinikainen K, Heinonen S, Eriksson K, et al. Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy[J]. Epilepsia, 2006, 47(1): 186-192. PMID: 16417548. DOI: 10.1111/j.1528-1167.2006.00386.x.
66 Hernández-Díaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects[J]. N Engl J Med, 2000, 343(22): 1608-1614. PMID: 11096168. DOI: 10.1056/NEJM200011303432204.
67 Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry[J]. Lancet Neurol, 2011, 10(7): 609-617. PMID: 21652013. DOI: 10.1016/S1474-4422(11)70107-7.
68 Mawer G, Clayton-Smith J, Coyle H, et al. Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate[J]. Seizure, 2002, 11(8): 512-518. PMID: 12464511. DOI: 10.1016/s1059-1311(02)00135-8.
69 Vajda FJ, Lander CM, Hitchcock A, et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences[J]. J Clin Neurosci, 2007, 14(7): 611-617. PMID: 17400456. DOI: 10.1016/j.jocn.2006.04.025.
70 Harden C, Lu C. Epilepsy in pregnancy[J]. Neurol Clin, 2019, 37(1): 53-62. PMID: 30470275. DOI: 10.1016/j.ncl.2018.09.008.
71 Battino D, Binelli S, Caccamo ML, et al. Malformations in offspring of 305 epileptic women: a prospective study[J]. Acta Neurol Scand, 1992, 85(3): 204-207. PMID: 1575005. DOI: 10.1111/j.1600-0404.1992.tb04029.x.
72 Mawer G, Briggs M, Baker GA, et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study[J]. Seizure, 2010, 19(2): 112-119. PMID: 20036166. PMCID: PMC2823982. DOI: 10.1016/j.seizure.2009.11.008.
73 Campbell E, Devenney E, Morrow J, et al. Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero[J]. Epilepsia, 2013, 54(1): 165-171. PMID: 23167802. DOI: 10.1111/epi.12001.
74 Cunnington MC. The international lamotrigine pregnancy registry update for the epilepsy foundation[J]. Epilepsia, 2004, 45(11): 1468. PMID: 15509254. DOI: 10.1111/j.0013-9580.2004.451105.x.
75 Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers[J]. Neurology, 2013, 80(4): 400-405. PMID: 23303847. DOI: 10.1212/WNL.0b013e31827f0874.
76 Rauchenzauner M, Ehrensberger M, Prieschl M, et al. Generalized tonic-clonic seizures and antiepileptic drugs during pregnancy: a matter of importance for the baby?[J]. J Neurol, 2013, 260(2): 484-488. PMID: 22955634. DOI: 10.1007/s00415-012-6662-8.
77 Thomas SV, Jeemon P, Pillai R, et al. Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala registry of epilepsy and pregnancy (KREP)[J]. Seizure, 2021, 93: 127-132. PMID: 34740142. DOI: 10.1016/j.seizure.2021.10.015.
78 Scheuerle AE, Holmes LB, Albano JD, et al. Levetiracetam pregnancy registry: final results and a review of the impact of registry methodology and definitions on the prevalence of major congenital malformations[J]. Birth Defects Res, 2019, 111(13): 872-887. PMID: 31124321. DOI: 10.1002/bdr2.1526.
79 Sabers A, Dam M, A-Rogvi-Hansen B, et al. Epilepsy and pregnancy: lamotrigine as main drug used[J]. Acta Neurol Scand, 2004, 109(1): 9-13. PMID: 14653845. DOI: 10.1034/j.1600-0404.2003.00200.x.